GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » ROA %

2cureX AB (OSTO:2CUREX) ROA % : -158.66% (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. 2cureX AB's annualized Net Income for the quarter that ended in Sep. 2023 was kr-40.66 Mil. 2cureX AB's average Total Assets over the quarter that ended in Sep. 2023 was kr25.62 Mil. Therefore, 2cureX AB's annualized ROA % for the quarter that ended in Sep. 2023 was -158.66%.

The historical rank and industry rank for 2cureX AB's ROA % or its related term are showing as below:

OSTO:2CUREX' s ROA % Range Over the Past 10 Years
Min: -86.07   Med: -22.35   Max: -3.97
Current: -86.07

During the past 8 years, 2cureX AB's highest ROA % was -3.97%. The lowest was -86.07%. And the median was -22.35%.

OSTO:2CUREX's ROA % is ranked worse than
79.42% of 1555 companies
in the Biotechnology industry
Industry Median: -34.99 vs OSTO:2CUREX: -86.07

2cureX AB ROA % Historical Data

The historical data trend for 2cureX AB's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB ROA % Chart

2cureX AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROA %
Get a 7-Day Free Trial -31.00 -25.65 -14.51 -26.63 -46.95

2cureX AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.84 -55.86 -70.27 -95.45 -158.66

Competitive Comparison of 2cureX AB's ROA %

For the Biotechnology subindustry, 2cureX AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2cureX AB's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's ROA % distribution charts can be found below:

* The bar in red indicates where 2cureX AB's ROA % falls into.



2cureX AB ROA % Calculation

2cureX AB's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-29.77/( (79.16+47.657)/ 2 )
=-29.77/63.4085
=-46.95 %

2cureX AB's annualized ROA % for the quarter that ended in Sep. 2023 is calculated as:

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-40.656/( (29.765+21.483)/ 2 )
=-40.656/25.624
=-158.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data. ROA % is displayed in the 30-year financial page.


2cureX AB  (OSTO:2CUREX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-40.656/25.624
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-40.656 / 0.348)*(0.348 / 25.624)
=Net Margin %*Asset Turnover
=-11682.76 %*0.0136
=-158.66 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


2cureX AB ROA % Related Terms

Thank you for viewing the detailed overview of 2cureX AB's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


2cureX AB (OSTO:2CUREX) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Copenhagen, DNK, DK-2100
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines